Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis by unknown
Tan et al. BMC Nephrology 2013, 14:63
http://www.biomedcentral.com/1471-2369/14/63RESEARCH ARTICLE Open AccessSerum levels and renal deposition of C1q
complement component and its antibodies
reflect disease activity of lupus nephritis
Ying Tan1†, Di Song1†, Li-hua Wu1,2, Feng Yu1* and Ming-hui Zhao1Abstract
Background: Lupus nephritis is considered to be a principal cause of morbidity and mortality in SLE. Few studies
focus on the association between anti-C1q antibodies in circulation and renal C1q deposition in human lupus
nephritis. In this study, we detected the serum levels of C1q, presence of anti-C1q antibodies in circulation, renal
C1q deposition and further analyzed their associations with clinical and pathological activity in a large cohort of
Chinese lupus nephritis patients.
Methods: Sera and renal biopsies from 218 consecutive patients with lupus nephritis with long-term follow up
data were studied. Sera were tested for levels of C1q and anti-C1q autoantibodies. Associations of levels of C1q,
anti-C1q autoantibodies with renal deposition of C1q, clinical and histopathological data and renal outcome were
further investigated.
Results: The levels of serum C1q were significantly lower in lupus nephritis than that in normal controls [33.81 ±
20.36 v.s. 61.97 ± 10.50 μg/ml (P < 0.001)]. The prevalence of anti-C1q antibodies, ratios of glomerular and vascular
deposition of C1q in patients with lupus nephritis were 42.7% (93/218), 71.6% (156/218) and 86.2% (188/218),
respectively. The serum C1q levels and anti-C1q antibodies were associated with SLEDAI scores (P < 0.001, P = 0.012,
respectively), renal total activity indices scores (P < 0.001, P < 0.001, respectively). Granular positive staining of C1q
and IgG by immunofluorescence was co-localized almost completely along the glomerular capillary wall and
mesangial areas. Patients with anti-C1q antibodies presented with significantly lower serum C1q levels than those
without it (23.82 [0.60, 69.62] μg/ml v.s. 37.36 [0.64, 82.83] μg/ml, P < 0.001). The presence of anti-C1q antibodies
was associated with the presence of glomerular C1q deposition (P < 0.001), but not with the presence of renal
vascular C1q deposition (P = 0.203).
Conclusion: Anti-C1q autoantibodies were closely associated with serum levels of C1q and glomerular deposition
of C1q. Kidney is at least one of the target organs of anti-C1q autoantibodies.
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Systemic lupus erythematosus (SLE) is an autoimmune
disease and is characterized by the production of various
autoantibodies. Lupus nephritis is considered to be a
principal cause of morbidity and mortality among dis-
eases involving the major organs [1].
C1q is the first component of the classical pathway,
which is involved in clearance of immune complexes
and apoptotic cells. Interestingly, recent studies showed
that C1q could also exert other immuno-regulatory
properties, including limiting the differentiation of
monocytes into dendritic cells [2] and immune com-
plex–induced interferon-α production in plasmacytoid
dendritic cells [3], and participating in neutrophil extra-
cellular trap (NET) degradation [4]. C1q is composed of
a collagenous portion and globular heads. Hereditary
deficiency of C1q is known to be a risk factor for the
development of SLE [5]. Patients with active SLE have
lower levels of C1q compared to patients with non-
active SLE. Furthermore, patients with lupus nephritis
showed lower levels of C1q compared with patients with
SLE without nephritis, and the presence of the C1q
component in isolated SLE immune complex correlated
with the presence of renal disease [6]. Anti-C1q anti-
bodies are prevalent in patients with active lupus neph-
ritis [7] and were thought to be closely associated with
renal involvement and predictive for a flare of nephritis
[8]. However, the pathogenesis of anti-C1q antibodies in-
volved in lupus nephritis remains unclear.
Animal studies indicated that immune deposition of
C1q and anti-C1q antibodies in the kidney was dependent
on the presence of glomerular IgG [9-11], while an
additional study indicated that anti-C1q autoantibodies
deposited in glomeruli but were only pathogenic in com-
bination with glomerular C1q-containing immune com-
plexes [12]. However, the composition of the glomerular
and extraglomerular immune complex deposits seems to
differ from each other, which indicate that there might be
different mechanisms involved in glomerular versus
extraglomerular lesions.
There are few published studies that focus on the asso-
ciation between anti-C1q antibodies in circulation and
renal C1q deposition in human lupus nephritis. In this
work, we detected the serum levels of C1q, presence of
anti-C1q antibodies in the circulation, and renal C1q de-
position, and further analyzed their associations with
clinical and pathological activity in a large cohort of
Chinese patients with lupus nephritis.
Methods
Patients
Sera and renal biopsies from 218 consecutive patients
with renal biopsy-proven lupus nephritis, diagnosed from
2000 to 2008 at Peking University First Hospital werecollected on the day of renal biopsy. All the patients ful-
filled the 1997 American College of Rheumatology revised
criteria for SLE [13].
Clinical evaluation
Clinical data including gender, presence and degree of fever,
malar rash, photosensitivity, oral ulcers, alopecia, arthritis,
serositis, neurologic disorder, anemia, leukocytopenia, thro-
mbocytopenia, hematuria, and leukocyturia were noted and
analyzed. The clinical disease activity was measured by the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) [14]. The response to therapy (complete remis-
sion, partial remission, relapse, or treatment failure) were
the same as in our previous works [15]. All the patients
were followed in our outpatient lupus nephritis clinic. The
primary end-point was defined as death, and secondary end
points were defined as end-stage renal disease (ESRD) or
doubling of serum creatinine levels.
Laboratory assessment
Serum antinuclear antibodies (ANA) were detected using
an indirect immunofluorescence assay (EUROIMMUN,
Lübeck, Germany) and anti-double-stranded DNA
antibodies were detected using a Crithidia luciliae indir-
ect immunofluorescence test (EUROIMMUN, Lübeck,
Germany). Anti-extractable nuclear antigen (ENA) anti-
bodies, including anti-Sm, anti-SSA, anti-SSB and anti-
RNP antibodies, were detected using immunodotting
assays (EUROIMMUN, Lübeck, Germany). Serum C3 was
determined using a rate nephelometry assay (Beckman-
Coulter, IMMAGE, USA; normal range > 0.85 g/L).
Renal histopathology
All the renal biopsy specimens were examined by light
microscopy, direct immunofluorescence and electron
microscopy techniques. Lupus nephritis was re-classified
according to the International Society of Nephrology/
Renal Pathology Society (ISN/RPS) 2003 classification
system [16].
Light microscopy examination
Renal biopsy specimens were fixed in 4.5% buffered for-
maldehyde. Consecutive serial 3 μm sections were used
for histological staining. Stains employed included haema-
toxylin and eosin (H&E), periodic acid-Schiff, silver me-
thenamine (Meth) and Masson’s trichrome. Pathological
parameters including activity indices (AI), and chronicity
indices (CI) were assessed by renal pathologists using a pre-
viously reported system involving semi-quantitative scoring
of specific biopsy features, with mild modification [17]. The
AI consists of endocapillary hypercellularity, cellular cres-
cents, karyorrhexis/fibrinoid necrosis, subendothelial hya-
line deposits, interstitial inflammation, and leukocyte
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crescents, tubular atrophy, and interstitial fibrosis.
Direct immunofluorescence examination
Fresh frozen renal specimens were stained immediately
after the renal biopsy with fluoresceinisothiocyanate-
labelled rabbit anti-human immunoglobulin G (IgG), im-
munoglobulin A (IgA), immunoglobulin M (IgM), C3c,
C1q and fibrin antibodies (DAKO A/S, Copenhagen,
Denmark). Results were graded from 0 to 4 according to
the intensity of fluorescence.
To study immune complexes deposited in renal vessels,
immunofluorescence staining was performed using rabbit
anti-human IgG, IgA, IgM, C3c, C1q, fibrin (DAKO) and
C4d (Abcam) on formalin-fixed paraffin-embedded tissue
(4 μm thick). Optimal antibody dilutions were pre-
determined. In brief, sections were deparaffinized and
rehydrated through a series of xylene and graded alcohols.
The sections were then treated with 0.4% pepsin
(Zhongshan Golden Bridge Biotechnology, Beijing, China)
for 40 min. Digestion was terminated by repeated wash-
ings in 0.01 mol/L phosphate buffered saline (PBS),
pH 7.4. Sections were immersed into freshly prepared 3%
hydrogen peroxide in methanol solution for 10 min at
room temperature to quench endogenous peroxidase ac-
tivity. To block non-specific staining, sections were incu-
bated with 3% BSA in PBS at room temperature for
30 min. The primary antibodies against IgG (diluted
1:5000 in PBS), IgA (1:1000), IgM (1:400), C3c (1:300),
C4d (1:400), C1q (1:50) and fibrin (1:1000) were added on
each section directly. Antibodies were incubated overnight
at 4°C. FITC-labeled goat anti-rabbit IgG (Zhongshan
Golden Bridge Biotechnology, Beijing, China; diluted 1:60)
was used as a secondary antibody at 37°C for 30 min. Sec-
tions were washed with PBS (pH 7.4) between each step
(5 min, three times). Finally, sections were stored shortly
at 4°C before being examined using an immunofluores-
cence microscope (Nikon Eclipse 80i, Japan). Sections of
renal tissue from patients diagnosed with lupus nephritis
were used as positive controls. Samples stained without
primary antibodies were used as negative controls.
Detection of co-localization of C1q and IgG on glomeruli by
immunofluorescence
Five μm sections from frozen renal biopsy tissues were
cut and placed onto slides, air-dried for 25 min at room
temperature, and fixed in pre-cooled acetone for 10 min
at 4°C. After three washes with phosphate buffered
saline (PBS), sections were incubated in 3% BSA for
30 min at room temperature. Tetramethylrhodamine
isothiocyanate (TRITC) -labeled rabbit anti-human IgG
(diluted 1:40; Dako, Copenhagen, Denmark) were incu-
bated 30 min at 37°C. After washing with PBS 3 times
for 3 min, mouse anti-human C1q (diluted 1:400;Abcam, Cambridge, UK) was added as primary antibody
for 30 min at 37°C. After another 3 × 3 min washes with
PBS, FITC-labeled goat anti-mouse IgG (diluted 1:30;
Zhongshan Golden Bridge Biotechnology, Beijing, China)
was used as the secondary antibody for 30 min at 37°C.
After washing with PBS 3 times for 3 min, the sections
were air-dried in the dark and mounted with citifluor.
Samples stained without primary antibodies were used as
negative controls. Sections were stored shortly at 4°C be-
fore being scored using a confocal microscope (Olympus
Viewer 1000, Japan).
Serum samples
Sera from patients with lupus nephritis were obtained
from peripheral blood at the time of renal biopsy. Sera
from 22 healthy controls (gender and age matched) were
collected as normal controls. All of the sera were stored
at −70°C until use.
Written informed consent was obtained for blood
sampling and renal biopsy from each patient. The research
was in compliance with the Declaration of Helsinki and
approved by the ethics committee of Peking University
First Hospital.
Detection of serum C1q levels using enzyme-linked
immunosorbent assay (ELISA)
Detection of serum C1q levels was performed by modi-
fying a previously described method [18]. Anti-human
C1q polyclonal antibody from rabbit (Dako, Denmark)
was diluted to 1:5000 (1.26 μg/ml) in 0.05 M bicarbonate
buffer (pH 9.6) and coated onto the wells of a polystyr-
ene microtitre plate (Nunc, Denmark). All plates were
coated with 50 μl of this solution and incubated over-
night at 4°C, then washed three times with 0.01 M PBST
and blocked with 200 μl PBST containing 1% BSA, 37°C
for 1 h. The following incubations were carried out at
37°C for 1 h, 50 μl total volume in each well, and all
plates were washed three times with PBST. Standards
and diluted serum sample (1:2,000 in PBST) were added
to their respective wells. All the samples were tested in
duplicate wells. Subsequently, horseradish peroxidase
(HRP)-conjugated goat anti-human IgG monoclonal anti-
body (Abcam) was diluted to 1:500. The reaction was de-
veloped with 3,30,5,50-Tetramethylbenzidine (TMB) liquid
substrate system and was stopped with 1 M H2SO4. The
results were recorded as the net optical absorbance at
450 nm and 570 nm in an ELISA reader (Bio-Rad 550,
Japan). The cutoff value of C1q was set as the mean - 2
SD of healthy blood donors.
Detection of anti-C1q IgG autoantibodies with ELISA
Anti-C1q IgG autoantibodies were detected using a pre-
viously published ELISA method [7]. In brief, purified
normal human C1q (Sigma, USA) was diluted at 5 μg/
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onto the wells of one-half of a polystyrene microtitre
plate (Costar, USA). The wells in the other half were
coated with the same bicarbonate buffer alone as
antigen-free wells to measure non-specific binding. The
volumes used in each well for this step and for subse-
quent steps was 100 μl. All incubations were carried out
at 37°C for 1 h, and all plates were washed three times
with 0.01 M PBS containing PBST. Wells were then
blocked with PBST containing 0.01% gelatin. The sera
diluted to 1:200 with PBST containing 1% BSA and
0.5 M NaCl, and were added in duplicate to both
antigen-coated and antigen-free wells. Each plate in-
cluded a blank control, negative control and a known
positive control. After incubation and washing, the wells
were then incubated with 1:5000 diluted horseradish
peroxidase (HRP)-conjugated goat anti-human IgG
(Zhongshan Biotech, China). The reaction was devel-
oped with a 0.1 M citrate phosphate buffer (pH 5.0)
containing 0.04% O-phenylenediamine (OPD) and 0.1%
H2O2, then the reaction was stopped with 1 M H2SO4.
The results were recorded as the net optical absorbance
(average value of antigen wells minus average value of
antigen-free wells) at 490 nm in an ELISA reader (Bio-
Rad 550, Japan) and expressed as percentage of the
known positive sample. The cutoff value was set as the
mean + 2 SD of healthy blood donors.Table 1 General clinical and renal histopathological profiles o
Number of patients 218 C3
Gender (male/female) 33/185 Ant
Age (mean ± SD) (years) 32.5 ± 11.3 Ant
Follow-up time (median, range) (months) 41 (1,360) Ant
Fever (non-infectious) No.(%) 69 31.7) Ant
Malar rash No.(%) 118 (54.1) Ant
Photosensitivity No.(%) 47 (21.6) Ant
Oral ulcer No.(%) 64 (29.4) Ant
Alopecia No.(%) 68 (31.2) SLE
Arthralgia No.(%) 115 (52.8) Act
Serositis No.(%) 34 (15.6) End
Neurologic disorder No.(%) 14 (6.4) Cel
Anemia No.(%) 147 (67.4) Kar
Leukocytopenia No.(%) 102 (46.8) Sub
Thrombocytopenia No.(%) 64 (29.4) Inte
Hematuria No.(%) 168 (77.1) Glo
Leukocyturia (non-infection) No.(%) 118 (54.1) Chr
Acute renal failure No.(%) 39 (17.9) Glo
Hemoglobin (mean ± SD) (g/l) 100.92 ± 26.36 Fib
Urine protein (median, range) (g/24 hours) 4.36 (0–17) Tub
Serum creatinine (median, range) (μmol/l) 82.0 (37,1000) Inte
SSA/SSB, Sjögren’s syndrome A/Bantigen; SSB, Sjögren’s syndrome B antigen; SLEDAIStatistical analysis
Statistical software SPSS 13.0 (SPSS, Chicago, IL, USA)
was employed for statistical analysis. Quantitative data
were expressed as mean ± SD., median with range (mini-
mum, maximum), or number (%). For comparison of
clinical and pathological features of patients, Mann–
Whitney Test, X2 test and Spearman’s correlation were
used. Survival analysis was performed using the log-rank
test. Statistical significance was considered as P <0.05.Results
General data of patients with lupus nephritis
The clinical and renal histopathological data of 218
lupus nephritis patients at the time of renal biopsy are
listed in Table 1.Levels of serum C1q in patients with lupus nephritis and
their associations with clinical and pathological features
Purified human C1q was used to establish the standard
curve. C1q could be detected by the sandwich ELISA at
a range of 0 μg/ml to 125 μg/ml. The average levels of
serum C1q were 33.81 ± 20.36 (0.60, 82.83) μg/ml in the
lupus nephritis group, which were significantly lower
than that in normal controls (61.97 ± 10.50 [46.05,
86.34] μg/ml, P < 0.001). The cutoff value for the lower
limit of detection of C1q was 40.97 μg/ml.f patients with lupus nephritis at renal biopsy
(mean ± SD) (g/l) 0.45 ± 0.23
i-nuclear antibody (ANA) (+) No.(%) 215 (98.6)
i-double stranded DNA antibody (ds-DNA) (+) No.(%) 153 (70.6)
i-SSA antibody (+) No.(%) 102 (46.8)
i-SSB antibody (+) No.(%) 25 (11.5)
i-Smith antibody(Sm) (+) No.(%) 53 (24.3)
i-ribonucleoprotein (RNP) antibody (+) No.(%) 66 (30.3)
i- cardiolipin antibody (+) No.(%) 16 (7.3)
DAI (mean ± s.d.) 17.6 ± 5.8
ivity indices (AI) score (median, range) 8 (0,19)
ocapillary hypercellualrity (median, range) 3 (0,-3)
lular crescents (median, range) 0 (0,6)
yorrhexis/fibrinoid necrosis (median, range) 0 (0,6)
endothelial hyaline deposits (median, range) 1 (0,3)
rstitial inflammatory cell infiltration (median, range) 1 (0,3)
merular leukocyte infiltration (median, range) 1 (0,12)
onicity indices (CI) score (median, range) 2 (0,10)
merular sclerosis (median, range) 0 (0,3)
rous crescents (median, range) 0 (0,3)
ular atrophy (median, range) 1 (0,3)
rstitial fibrosis (median, range) 1 (0,3)
, SLE Disease Activity Index.
Tan et al. BMC Nephrology 2013, 14:63 Page 5 of 10
http://www.biomedcentral.com/1471-2369/14/63Levels of serum C1q were correlated with age (r =
0.161, P = 0.018). There was no significant difference in
serum C1q levels between female and male with lupus
nephritis (P = 0.291). Patients with lower serum C1q
levels (<40.97 μg/ml) showed significantly higher levels
of SLEDAI (P < 0.001), significantly lower levels of C3









Number of patients (%) 93/218(42.7%) 125/218(57.3%)
Gender (male/female) 14/79 19/106
Age (mean ± SD) (years) 31.27 ± 9.96 33.47 ± 11.21
Clinical and laboratory data
Fever (non-infectious) No.(%) 31(33.3%) 38(30.4%)
Malar rash No.(%) 51(54,8%) 67(53,6%)
Photosensitivity No.(%) 20(21.5%) 27(21.6%)
Oral ulcer No.(%) 28(30.1%) 38(30.4%)
Alopecia No.(%) 30(32.3%) 38(30.4%)
Arthralgia No.(%) 60(64.5%) 55(44.0%)
Serositis No.(%) 13(14.0%) 21(16.8%)
Neurologic disorder No.(%) 7(7.5%) 7(5.6%)
Anemia No.(%) 73(78.5%) 74(59.2%)
Leukocytopenia No.(%) 49(52.7%) 53(42.4%)
Thrombocytopenia No.(%) 26(28.0%) 38(30.4%)
Hematuria No.(%) 79(36.2%) 89(40.8%)
Leukocyturia No.(%) 55(25.2%) 63(28.9)
Acute kidney injury No.(%) 18(8.3%) 21(9.6%)
Hemoglobin (mean ± SD.)
(g/l)
96.30 ± 25.78 104.36 ± 26.36
Urine protein (mean ± SD)
(g/24 hours)
4.42 ± 3.05 5.40 ± 3.39





antibody (ds-DNA) (+) No.(%)
71(76.3%) 82(65.6%)
Anti-SSA antibody (+) No.(%) 45(48.4%) 57(45.6%)







Anti- cardiolipin antibody (+)
No.(%)
10(10.8%) 6(4.8%)
SLEDAI 18.72 ± 5.70 16.74 ± 5.69
NS, no significance.DNA antibody (P = 0.003), hematuria (P = 0.021), and
anemia (P = 0.004; Table 2). The levels of serum C1q in
different pathological classes of lupus nephritis were
42.39 (9.61, 78.26) μg/ml in class II, 36.00 (0.92, 82.83)
μg/ml in class III, 27.21 (0.60, 77.07) μg/ml in class IV,
51.81(1.19, 81.98) μg/ml in class V, and 37.92 μg/ml in
class VI. There were significant differences in serum C1qodies, levels of C1q and clinical parameters of patients








NS 12/63 21/122 NS
NS 34.15 ± 10.92 31.69 ± 11.40 NS
NS 19(25.3%) 50(35.0%) NS
NS 42(56.0%) 76(53.1%) NS
NS 16(21.3%) 31(21.7%) NS
NS 20(26.7%) 44(30.8%) NS
NS 26(34.7%) 42(29.4%) NS
0.003 36(45.6%) 79(55.2%) NS
NS 10(13.3%) 24(16.8%) NS
NS 1(1.3%) 13(9.1%) NS
0.003 41(54.7%) 106(74.1%) 0.004
NS 23(30.7%) 79(55.2%) NS
NS 19(25.3%) 45(31.5%) NS
0.017 51(68.0%) 117(81.8%) 0.021
NS 34(45.3%) 84(58.7%) NS
NS 13(17.3%) 26(18.2%) NS
0.025 102.89 ± 31.52 99.89 ± 23.27 NS
NS 5.64 ± 3.70 4.64 ± 3.00 0.045
<0.001 0.60 ± 0.25 0.37 ± 0.17 <0.001
NS 73(97.3%) 142(99.3%) NS
NS 43(57.3%) 110(76.9%) 0.003
NS 43(57.3%) 59(41.3%) NS
NS 9(12.0%) 16(11.2%) NS
NS 21(28.0%) 32(22.4%) NS
NS 26(34.7%) 40(28.0%) NS
NS 2(2.7%) 14(9.8%) NS
0.012 15.47 ± 4.90 18.69 ± 5.89 <0.001
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The level in class IV was the lowest among the four clas-
ses (IV v.s. II, P = 0.046; IV v.s. III, P = 0.005; IV v.s. V,
P < 0.001; respectively).
The lower levels of serum C1q (<40.97 μg/ml) were
associated negatively with the renal activity indices score
(r = −0.327, P < 0.001), endocapillary hypercellularity (r =
−0.337, P < 0.001), cellular crescents (r =−0.182, P = 0.007)
fibrinoid necrosis (r = −0.310, P < 0.001), subendothelial
hyaline deposits (r = −0.312, P < 0.001), glomerular
leukocyte infiltration (r = −0.246 P < 0.001), and associ-
ated positively with glomerular sclerosis (r = 0.146, P =
0.031). No significant associations were found between
other indices (Table 3).
Prevalence of serum anti-C1q IgG auto-antibodies in
patients with lupus nephritis and their associations with
clinical and pathological characteristics
The cutoff value for detection of anti-C1q IgG auto-
antibodies was 29%. The prevalence of anti-C1q anti-
bodies in patients with lupus nephritis was 42.7% (93/
218), which was significantly higher than that in normal
controls (0/22). Patients with positive anti-C1q anti-
bodies showed significantly higher SLEDAI (P = 0.012),
lower levels of C3 (P < 0.001) and hemoglobin (P =
0.025), compared with those without anti-C1q antibodies
(Table 2). Anti-C1q antibodies were also associated with
arthralgia (P = 0.003), anemia (P = 0.003) and hematuria
(P = 0.017; Table 2). The prevalence of anti-C1q anti-
bodies in patients with type II, III, IV, V, and VI lupus
nephritis were 25.0% (2/8), 33.3% (13/39), 55.1% (70/Table 3 Associations between presence of anti-C1q autoantib











Activity Indices score 9(0,19) 7(0,16) 0.23
Endocapillary hypercellularity 3(0,3) 2(0,3) 0.24
Cellular crescents 2(0,6) 0(0,6) 0.16
Karyorrhexis/fibrinoid necrosis 2(0,6) 0(0,4) 0.17
Subendothelial hyaline deposits 1(0,3) 1(0,3) 0.17
Interstitial inflammation 1(0,3) 1(0,3) NS
Leukocyte infiltration 1(0,3) 1(0,3) 0.15
Chronicity Indices score 2(0,9) 2(0,10) NS
Glomerular sclerosis 0(0,3) 0(0,3) NS
Fibrous crescents 0(0,3) 0(0,3) NS
Tubular atrophy 1(0,3) 1(0,3) NS
Interstitial fibrosis 1(0,3) 1(0,3) NS
NS, no significance.127), 16.3% (7/43), and 100% (1/1), respectively. The
prevalence of anti-C1q antibodies in patients with dif-
fuse proliferative renal lesions (class IV) was significantly
higher than that in patients with non-diffuse prolifera-
tive renal lesions (class II, III, V) (55.1% [70/127] v.s.
36.7% [33/90]; P < 0.001). Anti-C1q antibodies were as-
sociated with most histopathological parameters of activ-
ity indices including activity indices score (P < 0.001),
endocapillary hypercellularity (P < 0.001), cellular cres-
cents (P = 0.013), karyorrhexis/fibrinoid necrosis (P =
0.009), subendothelial hyaline deposits (P = 0.012) and
leukocyte infiltration (P = 0.019; Table 3).
Co-localization of C1q and IgG deposited in glomerulis by
laser scanning confocal microscopy
The prevalence of glomerular and vascular deposition of
C1q in patients with lupus nephritis was 71.6% (156/
218) and 86.2% (188/218), respectively. Renal biopsies
from four patients with lupus nephritis with positive
anti-C1q autoantibodies were stained for C1q and IgG.
Granular positive staining of C1q and IgG by immuno-
fluorescence was shown along the glomerular capillary
wall and mesangial area and was co-localized almost
completely in the same areas (Figure 1).
Correlations among levels of serum C1q, autoantibodies
against C1q, glomerular and vascular depositions of C1q
in lupus nephritis
Patients positive for anti-C1q antibodies presented with
significantly lower serum C1q levels than those without












8(<0.001) 4(0,19) 9(0,19) −0.327(<0.001)
9(<0.001) 3(0,3) 1(0,3) −0.337(<0.001)
7(0.013) 2(0,6) 0(0,6) −0.182(0.007)
5(0.009) 2(0,6) 0(0,2) −0.310(<0.001)
1(0.012) 1(0,3) 0(0,3) −0.312(<0.001)
1(0,3) 1(0,3) NS






Figure 1 Co-localization of C1q and IgG staining in glomeruli in lupus nephritis. A&D. Granular positive staining of C1q by
immunofluorescence along the glomerular capillary wall and mesangial area in a patient with lupus nephritis. B&E. Granular positive staining of
IgG by immunofluorescence along the glomerular capillary wall and mesangial area in the same section in Figure 1A or D. C&F. C1q and IgG co-
localized completely along the glomerular capillary wall and mesangial area, merged in yellow. (Original magnification × 800).
Figure 2 Comparison of serum C1q levels in patients with
lupus nephritis with positive or negative anti-C1q antibodies
and normal controls. The horizontal lines indicated the median
value and range.
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serum C1q levels were not associated with the intensity
of glomerular or vascular C1q deposition in the kidneys
(P = 0.469, P = 0.198, respectively).
The presence of anti-C1q antibodies were associated
positively with the presence of glomerular deposition
(87.1% patients with anti-C1q antibodies [81 patients
with C1q deposition/93 patients with antibodies] vs.
60.0% patients without anti-C1q antibodies [75 patients
with C1q deposition/125 patients without antibodies],
P < 0.001), but not with the presence of vascular C1q de-
position (82.8% patients with anti-C1q antibodies [77 pa-
tients with C1q deposition/93 patients with antibodies] vs.
88.8% patients without anti-C1q antibodies [111 patients
with C1q deposition/125 patients without antibodies], P =
0.203). The intensity of glomerular deposition was not as-
sociated with the intensity of vascular deposition (r =
−0.081, P = 0.239).
Associations between levels of serum C1q, autoantibodies
against C1q, glomerular, vascular deposition of C1q and
renal outcomes
Levels of serum C1q, autoantibodies against C1q, or
glomerular or vascular deposition of C1q were found to
not be risk factors for long-term renal outcomes in lupus
nephritis using the log-rank test for univariate survival
analysis of renal prognosis (P = 0.200, P = 0.301, P =
0.548, P = 0.697, respectively). Patients were divided into
three groups according to C1q level (patients with “nor-
mal C1q” (> 40 μg/ml), “low levels of C1q” (20–40 μg/
ml) and “very low levels of C1q” (<20 μg/ml)). No sig-
nificant difference between the three groups was foundregarding long-term renal survival and relapse-free renal
survival (P = 0.237, P = 0.185, respectively) (Figure 3).
Discussion
The kidney is one of the most commonly involved or-
gans in SLE. C1q and its autoantibodies have been con-
sidered to be associated closely with SLE and lupus
Figure 3 (See legend on next page.)
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Figure 3 Comparison of renal outcomes and relapse-free renal survival among patients with different levels of C1q. A. Comparison of
renal outcomes among patients with different levels of C1q; B. Comparison of relapse-free renal survival among patients with different levels of
C1q. Group 1.patients with “normal C1q” (> 40 μg/ml); Group 2. patients with “low C1q” (20–40 μg/ml); Group 3. patients with “very low
C1q” (<20 μg/ml).
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tion of anti-C1q autoantibodies. Recently, Yasuhiro et al.
indicated that anti-C1q antibodies were associated with
SLE global activity but not specifically with active lupus
nephritis [19]. With a large lupus nephritis cohort in our
center, we first demonstrated associations among levels
of C1q, presence of anti-C1q antibodies, renal C1q de-
position and their correlations with clinical and patho-
logical disease activity of lupus nephritis, which might
shed a light on the roles of C1q and it autoantibodies in
lupus nephritis.
Previous studies have demonstrated a negative correl-
ation between anti-C1q autoantibodies and serum levels
of C1q in patients with lupus nephritis. Levels of C1q
were significantly lower in patients with lupus nephritis
and in active patients [20]. Animal studies indicated that
the severity of lupus nephritis seemed to correlate with
the amount of C1q present in the glomeruli [12]. In
addition, other studies have found that the presence of
anti-C1q antibodies was associated positively with glom-
erular C1q deposition [21].
In our study, we confirmed that the presence of anti-
C1q autoantibodies is associated with the intensity of
glomerular deposition of C1q, both of which were asso-
ciated with disease activity of SLE and lupus nephritis.
In addition, the intensity of glomerular deposition of
C1q was also associated with IgG and was co-localized
with IgG in the glomeruli. The co-localization indicated
that C1q could deposit on the kidney with immunoglobins,
including anti-C1q autoantibodies, which has been previ-
ously described by Mannik et al. [22]. This finding is
strengthened by the findings of Daha et al. who demon-
strated that anti-C1q autoantibodies may induce renal dis-
ease by deposition in glomeruli only together with C1q
and immune complex [12]. Thus, the kidneys are at least
one of the target organs of anti-C1q autoantibodies.
Though the intensity of vascular deposition of C1q was as-
sociated with vascular deposition of IgG and IgM, presence
of anti-C1q autoantibodies was not associated with the in-
tensity of vascular deposition of C1q. While a recent study
indicated that different immune complex might deposit in
glomerular and extraglomerular regions, the pathogenesis
of vascular lesions still needs further investigation [12].
Serum levels of C1q were not associated with glomerular
deposition of C1q or vascular deposition of C1q. This
indicates that serum C1q may contribute little to the de-
position of C1q in the kidneys, while local production of
C1q by endothelial cells [23,24], dendritic cells, andmacrophages in the kidneys might be the main source of
the local C1q deposition [25].
Animal studies suggest that immune deposition of
C1q and anti-C1q autoantibodies in the kidney is
dependent on the presence of glomerular IgG depos-
ition, and additional studies have indicated that anti-C1q
autoantibodies deposit in glomeruli, but are only patho-
genic in combination with glomerular C1q-containing
immune complexes, and deposition of C1q in the glom-
eruli, such as those that may form in glomerular C1q-
containing immune complexes, will induce overt renal
disease [12]. Our study supports the theory that auto-
antibodies of C1q are co-localized with C1q and other
immunoglobins in the glomeruli and might induce
glomerular injury in patients of lupus nephritis. The se-
verity was associated positively with the intensity of C1q
deposition in the glomeruli. However, the constitution of
the immune complex is still unclear. Previous studies in-
dicated that the anti-dsDNA antibody is the best sero-
logical biomarker for lupus nephritis. Recently Krishnan
et al. have reported that those cross-reacting with glom-
erular basement membrane components produced im-
mune deposits, [26] which suggested that anti-dsDNA
antibodies might be the component of immune complex.
Interestingly, recent studies indicated that anti-C-react-
ive protein (CRP) auto-antibodies and anti-PTX3 auto-
antibodies also correlated with histopathological activity
and disease activity in lupus nephritis [27,28]. As CRP
and PTX3 could bind to C1q as reported [29], and local
production of CRP and PTX3 in the kidneys were also
detected in some studies [30,31]. Thus, the correlations
between C1q, CRP, PTX3 and its auto-antibodies in the
formation of immune complex in lupus nephritis need
further investigation.Conclusions
In summary, anti-C1q autoantibodies were closely asso-
ciated with serum levels of C1q and glomerular depos-
ition of C1q, suggesting the kidney is at least one of the
target organs of anti-C1q autoantibodies.
Competing interests
All authors declare that they have no competing interest.
Authors’ contributions
Dr. YT carried out the immunoassays, participated in the design of the study,
performed the statistical analysis and drafted the manuscript. DS carried out
the immunoassays and drafted the manuscript. Dr. L-hW carried out the
renal histology studies. Prof. FY, M-hZ participated in the design of the study
Tan et al. BMC Nephrology 2013, 14:63 Page 10 of 10
http://www.biomedcentral.com/1471-2369/14/63and revised the manuscript. All authors read and approved the final
manuscript.Acknowledgements
This work was supported by grants of Chinese 973 project (No.
2012CB517702), National Natural Science Foundation of China (No.
81100497).
Author details
1Renal Division, Department of Medicine, Peking University First Hospital;
Institute of Nephrology, Peking University; Key laboratory of Renal Disease,
Ministry of Health of China; Key Laboratory of Chronic Kidney Disease
Prevention and Treatment, Ministry of Education of China, Beijing 100034,
Peoples’ Republic of China. 2Department of Nephrology, General Hospital of
Ningxia Medical University, Ningxia 750004, Peoples’ Republic of China.
Received: 7 October 2012 Accepted: 14 March 2013
Published: 19 March 2013References
1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC,
Aydintug AO, Chwalinska-Sadowska H, de Ramon E, et al: Morbidity and
mortality in systemic lupus erythematosus during a 10-year period: a
comparison of early and late manifestations in a cohort of 1,000
patients. Medicine (Baltimore) 2003, 82:299–308.
2. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B: C1q limits dendritic cell
differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci
U S A 2012, 109:E3160–E3167.
3. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, Sturfelt G,
Eloranta ML, Bengtsson AA: C1q inhibits immune complex-induced
interferon-alpha production in plasmacytoid dendritic cells: a novel link
between C1q deficiency and systemic lupus erythematosus
pathogenesis. Arthritis Rheum 2009, 60:3081–3090.
4. Elkon KB, Santer DM: Complement, interferon and lupus. Curr Opin
Immunol 2012, 24:665–670.
5. Kallel-Sellami M, Baili-Klila L, Zerzeri Y, Laadhar L, Blouin J, Abdelmoula MS,
Zitouni M, Fremeaux-Bacchi V, Ben Dridi MF, Makni S: Pediatric systemic
lupus erythematosus with C1q deficiency. Ann N Y Acad Sci 2007,
1108:193–196.
6. Greisman SG, Redecha PB, Kimberly RP, Christian CL: Differences among
immune complexes: association of C1q in SLE immune complexes with
renal disease. J Immunol 1987, 138:739–745.
7. Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH: Anti-C1q
antibodies and IgG subclass distribution in sera from Chinese patients
with lupus nephritis. Nephrol Dial Transplant 2009, 24:172–178.
8. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA: Anti-C1q
antibodies in nephritis: correlation between titres and renal disease
activity and positive predictive value in systemic lupus erythematosus.
Ann Rheum Dis 2005, 64:444–448.
9. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR:
Glomerular deposition of C1q and anti-C1q antibodies in mice following
injection of antimouse C1q antibodies. Clin Exp Immunol 2003, 132:32–39.
10. Trouw LA, Duijs JM, van Kooten C, Daha MR: Immune deposition of C1q
and anti-C1q antibodies in the kidney is dependent on the presence of
glomerular IgG. Mol Immunol 2003, 40:595–602.
11. Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos
A, van Kooten C, Daha MR: Anti-C1q autoantibodies in murine lupus
nephritis. Clin Exp Immunol 2004, 135:41–48.
12. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA,
Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR: Anti-C1q
autoantibodies deposit in glomeruli but are only pathogenic in
combination with glomerular C1q-containing immune complexes. J Clin
Invest 2004, 114:679–688.
13. Hochberg MC: Updating the American college of rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 1997, 40:1725.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of
the SLEDAI. A disease activity index for lupus patients. The committee
on prognosis studies in SLE. Arthritis Rheum 1992, 35:630–640.15. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH: Clinicopathological
characteristics and outcomes of patients with crescentic lupus nephritis.
Kidney Int 2009, 76:307–317.
16. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB,
Balow JE, Bruijn JA, Cook T, Ferrario F, et al: The classification of
glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc
Nephrol 2004, 15:241–250.
17. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse
proliferative lupus nephritis: identification of specific pathologic features
affecting renal outcome. Kidney Int 1984, 25:689–695.
18. Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U,
Marques ET: Alternative complement pathway deregulation is correlated
with dengue severity. PLoS One 2009, 4:e6782.
19. Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T,
Baba S, Hara M, Yamanaka H: Anti-C1q antibodies are associated with
systemic lupus erythematosus global activity but not specifically with
nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum
2011, 63:2436–2444.
20. Horak P, Hermanova Z, Zadrazil J, Ciferska H, Ordeltova M, Kusa L, Zurek M,
Tichy T: C1q complement component and -antibodies reflect SLE activity
and kidney involvement. Clin Rheumatol 2006, 25:532–536.
21. Chen Z, Wang GS, Wang GH, Li XP: Anti-C1q antibody is a valuable
biological marker for prediction of renal pathological characteristics in
lupus nephritis. Clin Rheumatol 2012, 31:1323–1329.
22. Uwatoko S, Mannik M: Low-molecular weight C1q-binding
immunoglobulin G in patients with systemic lupus erythematosus
consists of autoantibodies to the collagen-like region of C1q. J Clin Invest
1988, 82:816–824.
23. Bulla R, Agostinis C, Bossi F, Rizzi L, Debeus A, Tripodo C, Radillo O, De Seta
F, Ghebrehiwet B, Tedesco F: Decidual endothelial cells express surface-
bound C1q as a molecular bridge between endovascular trophoblast
and decidual endothelium. Mol Immunol 2008, 45:2629–2640.
24. Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EI: The C1q family of
proteins: insights into the emerging non-traditional functions. Front
Immunol 2012, 3:52.
25. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van
Kooten C, Roos A: Opsonization with C1q and mannose-binding lectin
targets apoptotic cells to dendritic cells. J Immunol 2004, 173:3044–3050.
26. Krishnan MR, Wang C, Marion TN: Anti-DNA autoantibodies initiate
experimental lupus nephritis by binding directly to the glomerular
basement membrane in mice. Kidney Int 2012, 82:184–192.
27. Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I: Serum levels of
autoantibodies against C-reactive protein correlate with renal disease
activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009,
11:R188.
28. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, Rampudda M,
Ghirardello A, Iaccarino L: SLE diagnosis and treatment: when early is
early. Autoimmun Rev 2010, 10:55–60.
29. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ,
Gingras AR, Tzima S, Vivanco F, Egido J, et al: Biochemical and functional
characterization of the interaction between pentraxin 3 and C1q.
Eur J Immunol 2003, 33:465–473.
30. Tan Y, Yu F, Qu Z, Su T, Xing GQ, Wu LH, Wang FM, Liu G, Yang L, Zhao MH:
Modified C-reactive protein might be a target autoantigen of TINU
syndrome. Clin J Am Soc Nephrol 2011, 6:93–100.
31. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A:
Pentraxins, humoral innate immunity and tissue injury. Curr Opin
Immunol 2008, 20:538–544.
doi:10.1186/1471-2369-14-63
Cite this article as: Tan et al.: Serum levels and renal deposition of C1q
complement component and its antibodies reflect disease activity of
lupus nephritis. BMC Nephrology 2013 14:63.
